New AI Model Improves Prediction of Therapeutic Peptide Function from Protein Sequences
Researchers have developed a lightweight convolutional neural network (CNN) ensemble that classifies therapeutic peptides by function directly from amino acid sequences, reducing false positive rates from over 60% to 2.1% compared to existing models. The model was trained on a dataset of 54,655 peptides across 48 functional categories and uses a novel negative sampling strategy based on Markov models to generate synthetic decoys. The advance could accelerate computational screening and generative design of therapeutic peptides, reducing reliance on costly experimental characterization.
A new study posted to bioRxiv introduces a CNN-based classifier for predicting the therapeutic function of peptides directly from their amino acid sequences. Trained on the largest therapeutic peptide dataset assembled to date—54,655 peptides spanning 48 functional categories—the five-model ensemble achieves 78.9% Micro F1 and 54.6% Macro F1 scores. A central methodological contribution is a statistically motivated negative sampling strategy that uses Markov models to generate synthetic non-therapeutic decoys at varying difficulty levels, dramatically reducing the false positive rate from over 60% seen in prior models to just 2.1%. On an independent generalization benchmark (TPpred-LE), the model performs comparably to a purpose-built competitor (55.3% vs. 57.9% Micro F1) while predicting four times more therapeutic functions and using four times fewer parameters. Interpretability analysis using a sparse L1-constrained model variant suggests the network learns biologically meaningful motifs, with convolutional filters capturing conserved functional patterns. The authors plan to release code and models publicly, which could facilitate integration into peptide drug discovery and generative design pipelines.
What's missing
The study is a preprint and has not yet undergone peer review, so findings should be treated as preliminary. The model's performance on real-world prospective screening tasks—beyond controlled benchmarks—has not been validated. It is also unclear how the model handles peptides from underrepresented or novel functional categories, and whether the Markov-generated decoys fully capture the diversity of naturally occurring non-therapeutic peptides.
What different sources said
- bioRxivCenter
Sequence-Based Therapeutic Peptide Classification with Augmented Negative Sampling
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.